Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
23 hedge funds and large institutions have $7.16M invested in Oncternal Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
15% more funds holding
Funds holding: 20 → 23 (+3)
6.02% more ownership
Funds ownership: 15.59% → 21.61% (+6%)
7% less capital invested
Capital invested by funds: $7.68M → $7.16M (-$521K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.94M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$477K |
| 3 |
Renaissance Technologies
New York
|
+$195K |
| 4 |
AC
Armistice Capital
New York
|
+$146K |
| 5 |
Morgan Stanley
New York
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$66.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.2K |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.58K |
| 4 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$6K |
| 5 |
BlackRock
New York
|
-$1.67K |
ONCT Hedge Fund Activity: Q3 2020 in Review
23 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2020, worth a combined $7.16M — down 6.8% from $7.68M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ONCT positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $2.94M. The largest seller was Millennium Management, cutting an estimated $66.5K.
- 23 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2020, up from 20 in Q2 2020.
- Funds reported $7.16M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2020, down 6.8% quarter-over-quarter.
- 4 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2020 and 1 closed out, a net change of +3 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2020 was Nantahala Capital Management, an estimated $2.94M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2020 was Millennium Management, an estimated $66.5K sold.
Based on aggregated 13F filings for Q3 2020.